Profound Medical Corp. (PROF): Revenue

Annual figures by period end, from SEC filings.

$16.10M

Year ended 2025-12-31

$19.09M

Trailing 12 months to 2026-06-30

2023-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$16.10M	+50.7%	2026-03-05, From 2025-01-01
2024-12-31	$10.68M	+48.4%	2026-03-05, From 2024-01-01
2023-12-31	$7.20M	n/a	2025-03-07, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Profound Medical Corp. (PROF)	2025-12-31	$16.10M	+50.7%
Biotricity Inc. (BTCY)	2026-03-31	$16.00M	+16.0%
Allurion Technologies, Inc. (ALUR)	2025-12-31	$15.23M	-52.6%
Vivos Therapeutics, Inc. (VVOS)	2025-12-31	$17.44M	+16.0%
Nephros Inc (NEPH)	2025-12-31	$18.79M	+32.7%
Sonoma Pharmaceuticals, Inc. (SNOA)	2026-03-31	$19.53M	+36.7%
Spectral AI, Inc. (MDAI)	2025-12-31	$19.65M	-33.6%
DarioHealth Corp. (DRIO)	2025-12-31	$22.36M	-17.3%
Baird Medical Investment Holdings Ltd (BDMD)	2025-12-31	$22.54M	-39.2%

Compare PROF, BTCY, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗